HUP0003331A2 - Eljárás a C-szerocsoportba nem besorolható adenovirális vektorok előállítására - Google Patents

Eljárás a C-szerocsoportba nem besorolható adenovirális vektorok előállítására

Info

Publication number
HUP0003331A2
HUP0003331A2 HU0003331A HUP0003331A HUP0003331A2 HU P0003331 A2 HUP0003331 A2 HU P0003331A2 HU 0003331 A HU0003331 A HU 0003331A HU P0003331 A HUP0003331 A HU P0003331A HU P0003331 A2 HUP0003331 A2 HU P0003331A2
Authority
HU
Hungary
Prior art keywords
serogroup
serotype
belonging
production
region
Prior art date
Application number
HU0003331A
Other languages
English (en)
Inventor
Erik Falck-Pedersen
Original Assignee
Cornell Research Foundation, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Research Foundation, Inc. filed Critical Cornell Research Foundation, Inc.
Publication of HUP0003331A2 publication Critical patent/HUP0003331A2/hu
Publication of HUP0003331A3 publication Critical patent/HUP0003331A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Electric Double-Layer Capacitors Or The Like (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)

Abstract

A találmány tárgya eljárás replikációs képességében hiányos, idegen,célba juttatandó gént tartalmazó, első (a másodiktól és a harmadiktólkülönböző) szerocsoportba tartozó első szerotípusú, az adenovirálisgenom E1 régiójának esszenciális génfunkciójában hiányos genommalrendelkező adenovírus előállítására egy sejtben, amely (i) egy másodikszerotípusú, második szerocsoportba tartozó adenovirális genom E1régiójának egy vagy több esszenciális génfunkcóját (ii) egy harmadikszerotípusú, harmadik szerocsoportba tartozó adenovirális genombólszármazó E4 régió egy vagy több génfunkcióját in trans biztosítja. Atalálmány szerinti megoldás alkalmazható az adenovírus-vektorokkalvégzett génterápiában és ezzel kapcsolatos in vi vo biológiai kutatásicélokra. Ó
HU0003331A 1997-05-22 1998-05-20 Method for the production of non-group c adenoviral vectors HUP0003331A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/861,773 US5849561A (en) 1997-05-22 1997-05-22 Method for the production of non-group C adenoviral vectors

Publications (2)

Publication Number Publication Date
HUP0003331A2 true HUP0003331A2 (hu) 2001-02-28
HUP0003331A3 HUP0003331A3 (en) 2003-01-28

Family

ID=25336722

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0003331A HUP0003331A3 (en) 1997-05-22 1998-05-20 Method for the production of non-group c adenoviral vectors

Country Status (15)

Country Link
US (1) US5849561A (hu)
EP (1) EP0988389B1 (hu)
JP (1) JP2001527420A (hu)
AT (1) ATE325885T1 (hu)
AU (1) AU743923B2 (hu)
BR (1) BR9809846A (hu)
CA (1) CA2289611C (hu)
DE (1) DE69834489T2 (hu)
HU (1) HUP0003331A3 (hu)
IL (1) IL133011A0 (hu)
MX (1) MXPA99010787A (hu)
NZ (1) NZ500920A (hu)
PL (1) PL336941A1 (hu)
SK (1) SK156799A3 (hu)
WO (1) WO1998053087A1 (hu)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
EP0833934B2 (en) * 1995-06-15 2012-08-15 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
US20040043489A1 (en) * 1998-07-08 2004-03-04 Menzo Havenga Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
US20030017138A1 (en) * 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
IL141403A0 (en) * 1998-08-28 2002-03-10 Univ Duke Deleted adenoviruses and methods of making and administering the same
US6929946B1 (en) * 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
EP1165817A1 (en) * 1999-04-06 2002-01-02 Merck & Co., Inc. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration
US6913922B1 (en) * 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) * 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US20050232900A1 (en) * 1999-05-18 2005-10-20 Crucell Holland B.V. Serotype of adenovirus and uses thereof
CN101302536A (zh) * 2000-02-02 2008-11-12 安增子摩祺株式会社 用于基因转移的病毒包膜载体
EP1157999A1 (en) * 2000-05-24 2001-11-28 Introgene B.V. Methods and means for enhancing skin transplantation using gene delivery vehicles having tropism for primary fibroblasts, as well as other uses thereof
WO2002024730A2 (en) * 2000-09-20 2002-03-28 Crucell Holland B.V. Transduction of dendritic cells using adenoviral vectors
DE60138403D1 (de) * 2000-09-26 2009-05-28 Crucell Holland Bv Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
US20040253210A1 (en) * 2001-08-30 2004-12-16 Marjorie Robert-Guroff Adenovirus type7 vectors
EP1573035B1 (en) * 2002-02-22 2015-09-02 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Brother of the regulator of imprinted sites (boris)
PT1497438E (pt) * 2002-04-25 2010-02-04 Crucell Holland Bv Meios e métodos para a produção de vectores de adenovírus
JP4237449B2 (ja) 2002-06-05 2009-03-11 国立医薬品食品衛生研究所長 アデノウィルスベクター
AU2003268145A1 (en) * 2002-08-22 2004-03-11 Merck And Co., Inc. Methods for propagating adenovirus and virus produced thereby
US20040166091A1 (en) * 2003-02-24 2004-08-26 Genvec, Inc. Materials and methods for treating disorders of the ear
WO2004083418A1 (en) * 2003-03-17 2004-09-30 Merck & Co., Inc. Adenovirus serotype 24 vectors, nucleic acids and virus produced thereby
EP1649028B1 (en) * 2003-07-25 2012-08-22 Genvec, Inc. Adenoviral vector-based vaccines
JP2007511507A (ja) 2003-11-14 2007-05-10 ジェンベク、インコーポレイティッド 癌を処置するための治療レジメン
PL2163260T3 (pl) 2004-01-23 2017-12-29 Msd Italia S.R.L. Szympansie adenowirusowe nośniki szczepionek
US20070207166A1 (en) 2004-04-12 2007-09-06 Genvec, Inc. Method of Using Adenoviral Vectors to Induce an Immune Response
EP1784493A2 (en) * 2004-09-01 2007-05-16 The Government of the United States of America as Represented by The Department of Health and Human Services Adenoviral vectors able to transduce apcs, potential use in immune response generation
US8450055B2 (en) * 2005-08-31 2013-05-28 The United States Of America As Represented By The Secretary Of The Navy Malaria antigen screening method
AU2006284756B2 (en) 2005-08-31 2012-06-07 Genvec, Inc. Adenoviral vector-based malaria vaccines
US9651543B2 (en) 2005-08-31 2017-05-16 The United States Of America As Represented By The Secretary Of The Navy Malaria antigen screening method
WO2007059461A2 (en) * 2005-11-10 2007-05-24 Genvec, Inc. Adenoviral vector-based foot-and-mouth disease vaccine
US20100278870A1 (en) * 2007-01-09 2010-11-04 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Adenoviral vector-based malaria vaccines
WO2009149252A1 (en) * 2008-06-04 2009-12-10 Cornell University Vaccines for prevention and treatment of addiction
US20120219583A1 (en) 2009-10-16 2012-08-30 Los Alamos National Security, Llc Nucleic acid sequences encoding expandable hiv mosaic proteins
EP2547362B1 (en) 2010-03-17 2021-08-25 Cornell University Disrupted adenovirus-based vaccine against drugs of abuse
WO2012083297A2 (en) 2010-12-17 2012-06-21 Genvec, Inc. Adenoviral vectors with modified hexon regions
WO2012088041A1 (en) 2010-12-20 2012-06-28 Genvec, Inc. Adenoviral vector-based dengue fever vaccine
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
WO2013154744A1 (en) 2012-04-13 2013-10-17 Cornell University Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction
WO2013180967A1 (en) 2012-05-29 2013-12-05 Genvec, Inc. Herpes simplex virus vaccine
WO2016037163A1 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating gene therapy anti-viral transfer vector immune responses
TWI710635B (zh) 2014-10-09 2020-11-21 美商珍維克公司 編碼人類無調同源物-1(hath1)之腺病毒載體
AU2018205496A1 (en) 2017-01-07 2019-07-25 Selecta Biosciences, Inc. Patterned dosing of immunosuppressants coupled to synthetic nanocarriers
JP7291398B2 (ja) 2017-03-30 2023-06-15 ザ ユニバーシティー オブ クイーンズランド キメラ分子およびその使用
WO2018208856A1 (en) 2017-05-08 2018-11-15 Gritstone Oncology, Inc. Alphavirus neoantigen vectors
AU2018347583A1 (en) 2017-10-13 2020-05-21 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector IgM responses
SG11202006400UA (en) 2018-01-04 2020-08-28 Iconic Therapeutics Inc Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
CN112384204B (zh) 2018-02-26 2023-03-14 安托瑞斯公司 致耐受性脂质体及其使用方法
AU2020265215A1 (en) 2019-04-28 2021-11-18 Selecta Biosciences, Inc. Methods for treatment of subjects with preexisting immunity to viral transfer vectors
WO2020243261A1 (en) 2019-05-28 2020-12-03 Selecta Biosciences, Inc. Methods and compositions for attenuated anti-viral transfer vector immune response
BR122024002387A2 (pt) 2019-05-30 2024-03-12 Gritstone Bio, Inc. Vetores de adenovírus, composição farmacêutica, sequência de nucleotídeo isolada, célula isolada, vetor, kit, usos de um vetor, método para fabricar o vetor, métodos para produzir um vírus e vetor viral
JP2022551483A (ja) 2019-10-08 2022-12-09 トラスティーズ オブ ボストン カレッジ 複数の異なる非天然アミノ酸を含有するタンパク質、並びにそのようなタンパク質の製造方法及び使用方法
CN115484978A (zh) 2020-03-05 2022-12-16 尼奥克斯医疗有限公司 使用免疫细胞治疗癌症的方法和组合物
WO2022032196A2 (en) 2020-08-06 2022-02-10 Gritstone Bio, Inc. Multiepitope vaccine cassettes
WO2023064367A1 (en) 2021-10-12 2023-04-20 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2023172624A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA858044B (en) * 1984-11-01 1987-05-27 American Home Prod Oral vaccines
EP0911413A3 (en) * 1992-12-03 2000-11-15 Genzyme Corporation Minimal adenovirus-based gene therapy vector
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
ES2196018T3 (es) * 1993-08-11 2003-12-16 Wyeth Corp Vacunas de adenovirus recombinantes.
US5543328A (en) * 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
EP0784690B1 (en) * 1994-06-10 2006-08-16 Genvec, Inc. Complementary adenoviral vector systems and cell lines
AU3551195A (en) * 1994-09-23 1996-04-09 Somatix Therapy Corporation Chimeric adenovirus for gene delivery
US5837511A (en) * 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors

Also Published As

Publication number Publication date
PL336941A1 (en) 2000-07-17
HUP0003331A3 (en) 2003-01-28
JP2001527420A (ja) 2001-12-25
NZ500920A (en) 2001-04-27
DE69834489D1 (de) 2006-06-14
WO1998053087A1 (en) 1998-11-26
CA2289611A1 (en) 1998-11-26
AU743923B2 (en) 2002-02-07
CA2289611C (en) 2009-11-03
DE69834489T2 (de) 2006-09-07
AU7584998A (en) 1998-12-11
IL133011A0 (en) 2001-03-19
EP0988389B1 (en) 2006-05-10
MXPA99010787A (es) 2005-12-12
BR9809846A (pt) 2000-06-20
SK156799A3 (en) 2000-05-16
EP0988389A1 (en) 2000-03-29
ATE325885T1 (de) 2006-06-15
US5849561A (en) 1998-12-15

Similar Documents

Publication Publication Date Title
HUP0003331A2 (hu) Eljárás a C-szerocsoportba nem besorolható adenovirális vektorok előállítására
Sharma et al. Mitochondrial DNA integrity: role in health and disease
Da Costa et al. Molecular approaches to diagnose Diamond-Blackfan anemia: The EuroDBA experience
Terai et al. Immortalization of human fetal cells: the life span of umbilical cord blood-derived cells can be prolonged without manipulating p16INK4a/RB braking pathway
Shoichet et al. Frataxin promotes antioxidant defense in a thiol-dependent manner resulting in diminished malignant transformation in vitro
Kiritsi et al. Revertant mosaicism in a human skin fragility disorder results from slipped mispairing and mitotic recombination
CA2338541A1 (en) Genetically modified cd34-negative adherently growing stem cells and their use in gene therapy
HUP0302320A2 (hu) Rekombináns konstrukciók és génexpresszió csökkentésére történő alkalmazásuk
HUP0301318A2 (hu) Replikáció-defektív rekombináns adenovírus mutáns fő késői promóterrel
Rostami et al. A critical role for extracellular DNA in dental plaque formation
Bigot et al. Hypoxia differentially modulates the genomic stability of clinical-grade ADSCs and BM-MSCs in long-term culture
EP1923467A3 (en) Adenovirus vectors for gene therapy
HUP0001937A2 (hu) Új vegyületek, eljárás előállításukra és alkalmazásuk nukleinsavak sejtekbe való bevitelére
BR9914643A (pt) Vetores adeno-associados para expressão dofator viii por células alvo
DE59913833D1 (de) Strukturprotein von aav, seine herstellung und verwendung
Harhouri et al. Antisense-based progerin downregulation in hgps-like patients’ cells
AUPN477695A0 (en) Gene therapy
Lange et al. A case of a canine pigmented plaque associated with the presence of a Chi‐papillomavirus
WO2003010336A3 (de) Molekulare marker beim hepatozellulären karzinom
Eberherr et al. Rescue of STAT3 function in hyper-IgE syndrome using adenine base editing
ATE386130T1 (de) Adenovirale vektoren für die gentherapie
ID27442A (id) Oligonukleotida untuk amplifikasi dan deteksi asam inti sel epstein barr (ebv)
Ma et al. Reactivation of γ-globin expression using a minicircle DNA system to treat β-thalassemia
BR9811014A (pt) "região concentrada reguladora de gene especìfica para semente precoce"
Belmar-López et al. Mesenchymal stem cells delivery in individuals with different pathologies: multimodal tracking, safety and future applications